MDACC Study No:2012-1091 ( NCT No: NCT01742299)
Title:An open label, multi-center imatinib roll-over protocol for patients who have completed a previous Novartis sponsored imatinib study and are judged by the investigator to benefit from continued imatinib treatment
Principal Investigator:Jorge Cortes
Treatment Agent:Gleevec; STI571
Study Status:Closed
Study Description:The goal of this clinical research study is to allow leukemia patients on
Protocol DM99-232 or DM99-367 to continue receiving Gleevec (imatinib mesylate)
after those studies close. Researchers also want to collect long-term safety
data on patients receiving the drug.

Imatinib mesylate is designed to bind to certain proteins on the tumor cells,
which may prevent the cells from growing.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:N/A
Treatment Agents:Gleevec
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Novartis
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults